CRVS Corvus Pharmaceuticals Inc
Price (delayed)
$5.61
Market cap
$360.48M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.92
Enterprise value
$356.16M
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells
Highlights
The debt has plunged by 79% YoY and by 49% from the previous quarter
Corvus Pharmaceuticals's net income has shrunk by 151% QoQ and by 88% YoY
The EPS has shrunk by 109% QoQ and by 44% YoY
Key stats
What are the main financial stats of CRVS
Market
Valuations
Earnings
Shares outstanding
64.26M
Market cap
$360.48M
Enterprise value
$356.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
28.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$25.09M
Net income
-$56.83M
EBIT
-$56.83M
EBITDA
-$56.74M
Free cash flow
-$22.13M
Per share
Balance sheet
Liquidity
EPS
-$0.92
EPS diluted
-$0.92
Free cash flow per share
-$0.33
Book value per share
$0.2
Revenue per share
$0
TBVPS
$0.88
Total assets
$58.82M
Total liabilities
$46.41M
Debt
$354,000
Equity
$12.41M
Working capital
-$3.49M
Debt to equity
0.03
Current ratio
0.92
Quick ratio
0.9
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-108.8%
Return on equity
-167.5%
Return on invested capital
-228.4%
Return on capital employed
-458%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRVS stock price
How has the Corvus Pharmaceuticals stock price performed over time
Intraday
5.06%
1 week
10.43%
1 month
-3.77%
1 year
179.1%
YTD
4.86%
QTD
4.86%
Financial performance
How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.09M
Net income
-$56.83M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has shrunk by 151% QoQ and by 88% YoY
The operating income has declined by 7% since the previous quarter and by 7% year-on-year
Growth
What is Corvus Pharmaceuticals's growth rate over time
Valuation
What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
28.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 109% QoQ and by 44% YoY
Corvus Pharmaceuticals's equity has shrunk by 76% QoQ and by 72% YoY
Efficiency
How efficient is Corvus Pharmaceuticals business performance
Corvus Pharmaceuticals's return on invested capital has shrunk by 197% QoQ
The ROE has dropped by 175% year-on-year
The company's return on assets has shrunk by 143% QoQ and by 113% YoY
Dividends
What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRVS.
Financial health
How did Corvus Pharmaceuticals financials performed over time
The total assets is 27% more than the total liabilities
The quick ratio has plunged by 80% YoY and by 75% from the previous quarter
CRVS's current ratio has plunged by 80% YoY and by 75% from the previous quarter
The debt is 97% less than the equity
The debt to equity has soared by 200% since the previous quarter but it has declined by 25% year-on-year
The debt has plunged by 79% YoY and by 49% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.